What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to publicly disclose Pfizer's financial guidance for the full year 2025 and to reaffirm its financial guidance for the full year 2024, in accordance with Regulation FD.

Where can I find the detailed financial guidance mentioned in the filing?

The detailed financial guidance is provided in the press release dated December 17, 2024, which is furnished as Exhibit 99.1 to this 8-K filing.

Does this filing contain updated financial statements?

No, this specific 8-K filing does not contain updated financial statements. It primarily serves as a disclosure vehicle for forward-looking financial guidance through a press release.

When was the information regarding the financial guidance officially released?

The press release containing the financial guidance was issued on December 17, 2024.

PFE 8-K: Regulation FD — Dec 17, 2024

Summary

Pfizer Inc. (PFE) has filed a Form 8-K to disclose important forward-looking financial information to investors. The company issued a press release on December 17, 2024, which provides its financial guidance for the full year 2025 and reaffirms its financial guidance for the full year 2024. This proactive disclosure is designed to keep the market informed about the company's financial expectations and strategic outlook.

Key Highlights

1Pfizer issued its full-year 2025 financial guidance.
2Pfizer reaffirmed its full-year 2024 financial guidance.
3The information was disclosed via a press release furnished on December 17, 2024.
4The press release is included as Exhibit 99.1 to the 8-K filing.
5This filing serves to ensure compliance with Regulation FD by providing material non-public information to all investors simultaneously.

PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 17, 2024)

Summary

Key Highlights

Frequently Asked Questions